Neurodegenerative Disorders Research

Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
ABN: 86 139 590 319
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: enquiries@ndr.org.au
Web: www.ndr.org.au

TRx Frontotemporal Dementia Study

Aim

To demonstrate the efficacy of Leuco-methylthioninium bis (hydromethanesulfonate) (LMTM), as assessed by change in Addenbrooke's Cognitive Examination Revised and Modified Alzheimer's Disease Cooperative Study – Clinical Global Impression of Change, on subjects with Behavioral Variant Frontotemporal Dementia (bvFTD).

Phase III

A global double-blind, placebo-controlled, randomized, parallel group, 12-month safety and efficacy trial of LMTM in subjects with bvFTD.

Hypothesis

LMTM dissolves neurotoxic micro-tubular associated protein tau and protein TDP-43, proteins critical in the pathogenesis of FTD, thereby preventing their aggregation and slowing the progression of bvFTD.

Status

Now enrolling

Study Code: TRx 237-007

Ethics approval

Bellberry Ethics Committee

Funding

TauRx Therapeutics

Criteria

To be eligible for this study subjects must:

- be less than 70 years old,
- have a Mini-Mental State Examination (MMSE) score of greater than 20,
- have a carer for at least 12 hours per week who will accompany subject to visits.

Duration of study

12 months

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: research@ndr.org.au